Gene therapies to treat rheumatoid arthritis have evolved slowly, but one is ready to move into human trials and an ...

Patients receiving an immune checkpoint inhibitor for a neoplasm face an increased risk for rheumatoid arthritis, an observational study found.

AnaptysBio’s Phase IIb trial of its rheumatoid arthritis (RA) treatment, rosinilimab, has seen some patients achieve the ...

Understand RA from early to advanced stages. Explore symptoms, treatments, and lifestyle tips to manage rheumatoid arthritis ...

Indian scientists have created an innovative self-actuating drug delivery system for Rheumatoid Arthritis, providing precise ...

Rheumatoid arthritis (RA) is an inflammatory arthritis characterized by chronic joint inflammation, cartilage degradation, and bone erosion.

The positive trial results have not only demonstrated rosnilimab's potential in treating RA but have also validated AnaptysBio's scientific approach in targeting PD-1 co-inhibitory receptors on ...

AnaptysBio stock whipsawed Wednesday despite promising results for its experimental rheumatoid arthritis treatment.

Achieved statistical significance on primary endpoint at Week 12 on mean change from baseline DAS-28 CRP across all rosnilimab doses vs.

Getting diagnosed and starting treatment early can help minimize symptoms, slow the progression of the disease, and improve long-term quality of life. In the early stages of RA, the immune system ...